Q1 2024 revenue of $21.1 million excluding discontinued operations and NY increased 44.5% year-over-year –
– Submitted a substantial legal filing on May 2nd in the ongoing litigation with Verano –
MGC Pharmaceuticals Ltd ('MGC Pharma' or 'the Company'), an EU based bio-pharma company specialising in the production and development of phytocannabinoid-derived medicines, is pleased to announce that it has signed a binding US Market Supply and Distribution Agreement (US Supply Agreement) with US company, AMC Holdings Inc (AMC), with minimum orders of US$24 million for MGC products including CannEpil®, CogniCann® and CimetrA™ over the initial 3 year period.
Key Highlights:
Q1 2024 revenue of $21.1 million excluding discontinued operations and NY increased 44.5% year-over-year –
– Submitted a substantial legal filing on May 2nd in the ongoing litigation with Verano –
– Company announces launch of Hi*AF and Boundary Waters branded beverages –
MINNEAPOLIS, May 07, 2024 (GLOBE NEWSWIRE) -- Goodness Growth Holdings, Inc. ("Goodness Growth" or the "Company") (CSE: GDNS; OTCQX: GDNSF), a cannabis company committed to providing safe access, quality products and great value to its customers, today reported financial results for its first quarter ended March 31, 2024. Key financial results are presented below in summary form with supporting commentary and discussion from management of certain key operating metrics which the Company uses to judge its performance. All currency figures referenced herein are denominated in U.S. dollars.
Summary of Key Financial Metrics | |||
Three Months Ended | |||
March 31, | |||
US $ in millions | 2024 | 2023 | Variance |
GAAP Revenue | $24.1 | $19.1 | 26.2% |
Revenue (excluding discontinued operations & NY) | $21.1 | $14.6 | 44.5% |
GAAP Gross Profit | $12.2 | $9.5 | 28.6% |
Gross Profit Margin | 50.8 % | 49.9 % | 90 bps |
SG&A Expenses | $7.1 | $7.2 | -1.5% |
SG&A Expenses (% of Sales) | 29.3 % | 37.5 % | 880 bps |
Operating Income (Loss) | $4.8 | $0.4 | 1191.6% |
Operating Income Margin | 19.8 % | 1.9 % | 1,780 bps |
EBITDA* | $6.8 | $1.4 | 370.5% |
EBITDA Margin | 28.2 % | 7.6 % | 2,060 bps |
* 1Q24 EBITDA includes a $1.3 million gain on Grown Rogue warrants which are marked to market at each period end | |||
Management Commentary
Chief Executive Officer Josh Rosen commented, "Our first quarter results reflect a continuation of the trends we observed during the fourth quarter, with continued improvements in operating and financial performance driven by the commencement of adult-use sales in Maryland in July 2023. In 2024, our teams remain focused on executing the key tenets of our CREAM & Fire strategy. As it relates to our divestiture process in New York, we continue to make progress with Ace Venture Enterprises and are also anticipating receiving approval to sell wholesale into the adult-use market shortly. With a short-term extension completed last week, we are also close to finalizing a longer-term extension with our senior secured lender, which has been supported by our progress with the New York divestiture and improved operating performance; that said our overall credit metrics have significant room for improvement and we continue to feel the pain of what we believe was the wrongful termination of our merger agreement with Verano."
Amber Shimpa, President and CEO of Vireo Health of Minnesota, commented, "Our operational key performance indicators continued to show strong improvements during the first quarter, and we continue to demonstrate market outperformance in Maryland's adult-use market. This past April 20 th holiday we were also pleased to build upon the success of our Hi*AF brand of vapes in Maryland with the launch our new Hi*AF and Boundary Waters branded cannabis beverages in our home market in Minnesota. We believe these new product introductions will help drive brand awareness ahead of the launch of adult-use sales in 2025, and we are looking forward to sharing additional details regarding our plans to prepare for Minnesota's adult-use launch later this year."
Core Market KPIs 1 | |||
Three Months Ended | |||
US $ in millions | March 31, | ||
2024 | 2023 | Variance | |
Total Flower Harvested (lbs) | 2,295 | 1,720 | 33.4% |
% "A" Flower 2 | 50.6 % | 47.9 % | 270 bps |
Total Retail Revenue | $17.8 | $13.1 | 36.2% |
Same Store Sales Growth | - | - | 36.2% |
Minnesota | - | - | 2.4 % |
Maryland | - | - | 190.8 % |
Total Wholesale Revenue | $3.4 | $1.6 | 114.4% |
1 Core Markets refer to the Company's operations in Maryland and Minnesota. | |||
2 "A Flower" refers to produced biomass that meet the Company's highest internal standards for flower quality, size, and appearance. | |||
Other Events
On April 1, 2024, the Company announced that it has executed a binding term sheet with ACE Venture Enterprises, Inc. ("Ace"), whereby Ace will acquire Goodness Growth Holdings subsidiary, Vireo Health of New York, pending regulatory approval. Terms of the transaction include a purchase price between $3.0 and $5.0 million for Vireo Health of New York's licenses, inventory and assets, an investment of $20.0 million from Ace for the development of the Johnstown, NY cannabis cultivation and manufacturing campus, and Ace's assumption of the Johnstown lease agreement with Innovative Industrial Properties. The parties also committed to a collaborative advisory agreement that retains Goodness Growth's management and compliance oversight in return for an approximate 15 percent share of net profits.
On May 1, 2024, the Company announced several leadership and corporate updates related to the day-to-day management of its business. Josh Rosen, who had served as Interim CEO since February of 2023, was appointed as Chief Executive Officer, effective immediately. The Company also provided updates regarding additional recent key personnel hires, details regarding a temporary extension of its credit agreement with its senior secured lender until June 14, 2024, and its planned name change to Vireo during the second quarter of 2024.
On May 2, 2024, the Company announced that it filed an application with the Supreme Court of British Columbia for summary determination in its ongoing litigation with Verano Holdings, Inc. ("Verano"). Goodness Growth is seeking damages of US $860.9 million from Verano, as well as other costs and legal fees, based on Verano's breach of contract and of its duty of good faith and honest performance. While the Company's filing of its application for summary determination reflects its belief that Verano's defense against its claims of unlawful conduct is without merit, Goodness Growth can make no assurances regarding the expected timeframe to resolve this litigation, or its ability to recover damages from Verano.
Balance Sheet and Liquidity
As of March 31, 2024, total current assets were $147.2 million, including cash on hand of $12.6 million. Total current liabilities were $184.2 million, including $88.4 million in liabilities held for sale related to the Company's businesses in the State of New York. As of March 31, 2024, the Company had a total of 234,937,843 shares outstanding on the treasury method basis.
Launch of Hi*AF & Boundary Waters Branded Beverages
On April 20, 2024, the Company launched its new lines of Hi*AF and Boundary Waters low-dose hemp-derived THC beverages in its home market of Minnesota. The Company's launch of beverages represents the culmination of months of work to establish a position in a growing sales channel within Minnesota with potential for expansion across the United States.
Amber Shimpa commented, "In a very short timeframe, Minnesota has established a robust market for low-dose THC product consumption both onsite in many bars, restaurants, and breweries, as well as at retail points of sale throughout the State. We have had a front row seat to this evolution and believe beverages represent an important sales channel that will drive greater adoption of cannabis consumption with new consumers as the industry continues to mature. Our beverages strategy reflects a capital light, low risk entry into this market with low-dose hemp-derived THC beverage products, and provides an attractive marketing opportunity to seed our brands ahead of the launch of adult-use sales in 2025."
Conference Call and Webcast Information
Goodness Growth management will host a conference call with research analysts today, May 7, 2024, at 4:30 p.m. ET (3:30 p.m. CT) to discuss its financial results for its first quarter ended March 31, 2024. Interested parties may attend the conference call by dialing 1-800-715-9871 (Toll-Free) (US and Canada) or 1-646-307-1963 (Toll) (International) and referencing conference ID number 3718174.
A live audio webcast of this event will also be available in the Events & Presentations section of the Company's Investor Relations website and via the following link:
https://events.q4inc.com/attendee/586704075 .
About Vireo & Goodness Growth
Vireo (Goodness Growth) was founded as a pioneer in medical cannabis in 2014 and sustained with an entrepreneurial drive that fuels our ongoing commitment to serve and delight our key stakeholders, most notably our customers, our employees, our shareholders, our industry collaborators, and the communities in which we live and operate. We work every day to get better and our team prioritizes 1) empowering and supporting strong local market leaders and 2) strategic, prudent capital and human resource allocation. For more information, please visit www.vireohealth.com .
Additional Information
Additional information relating to the Company's first quarter 2024 results will be available on EDGAR and SEDAR later today. Goodness Growth refers to certain non-GAAP financial measures such as Earnings Before Interest, Taxes, Depreciation and Amortization (EBITDA) in circumstances in which the Company believes that doing so provides additional perspective and insights when analyzing the core operating performance of the business. These measures do not have any standardized meaning and may not be comparable to similar measures presented by other issuers. Please see the Supplemental Information and Reconciliation of Non-GAAP Financial Measures at the end of this news release for more detailed information regarding non-GAAP financial measures.
Contact Information
Investor Inquiries: Sam Gibbons Investor Relations investor@vireohealth.com (612) 314-8995 | Media Inquiries: Amanda Hutcheson Senior Manager, Communications amandahutcheson@goodnessgrowth.com (919) 815-1476 |
Forward-Looking Statement Disclosure
This press release contains "forward-looking information" within the meaning of applicable United States and Canadian securities legislation. To the extent any forward-looking information in this press release constitutes "financial outlooks" within the meaning of applicable United States or Canadian securities laws, this information is being provided as preliminary financial results; the reader is cautioned that this information may not be appropriate for any other purpose and the reader should not place undue reliance on such financial outlooks. Forward-looking information contained in this press release may be identified by the use of words such as "should," "believe," "estimate," "would," "looking forward," "may," "continue," "expect," "expected," "will," "likely," "subject to," "transformation," and "pending," variations of such words and phrases, or any statements or clauses containing verbs in any future tense. These statements should not be read as guarantees of future performance or results. Forward-looking information includes both known and unknown risks, uncertainties, and other factors which may cause the actual results, performance, or achievements of the Company or its subsidiaries to be materially different from any future results, performance, or achievements expressed or implied by the forward-looking statements or information contained in this press release. Financial outlooks, as with forward-looking information generally, are, without limitation, based on the assumptions and subject to various risks as set out herein and in our Annual Report on Form 10-K filed with the Securities Exchange Commission. Our actual financial position and results of operations may differ materially from management's current expectations and, as a result, our revenue, EBITDA, and cash on hand may differ materially from the values provided in this press release. Forward-looking information is based upon a number of estimates and assumptions of management, believed but not certain to be reasonable, in light of management's experience and perception of trends, current conditions, and expected developments, as well as other factors relevant in the circumstances, including assumptions in respect of current and future market conditions, the current and future regulatory environment, and the availability of licenses, approvals and permits.
Although the Company believes that the expectations and assumptions on which such forward-looking information is based are reasonable, the reader should not place undue reliance on the forward-looking information because the Company can give no assurance that they will prove to be correct. Actual results and developments may differ materially from those contemplated by these statements. Forward-looking information is subject to a variety of risks and uncertainties that could cause actual events or results to differ materially from those projected in the forward-looking information. Such risks and uncertainties include, but are not limited to: risks related to the timing and content of adult-use legislation in markets where the Company currently operates; current and future market conditions, including the market price of the subordinate voting shares of the Company; risks related to epidemics and pandemics; federal, state, local, and foreign government laws, rules, and regulations, including federal and state laws and regulations in the United States relating to cannabis operations in the United States and any changes to such laws or regulations; operational, regulatory and other risks; execution of business strategy; management of growth; difficulties inherent in forecasting future events; conflicts of interest; risks inherent in an agricultural business; risks inherent in a manufacturing business; liquidity and the ability of the Company to raise additional financing to continue as a going concern; the Company's ability to meet the demand for flower in Minnesota; risk of failure in the lawsuit with Verano and the cost of that litigation; our ability to dispose of our assets held for sale at an acceptable price or at all; and risk factors set out in the Company's Form 10-K for the year ended December 31, 2023, which is available on EDGAR with the U.S. Securities and Exchange Commission and filed with the Canadian securities regulators and available under the Company's profile on SEDAR at www.sedar.com .
The statements in this press release are made as of the date of this release. Except as required by law, we undertake no obligation to update any forward-looking statements or forward-looking information to reflect events or circumstances after the date of such statements.
Supplemental Information
The financial information reported in this news release is based on unaudited financial statements for the first fiscal quarter ended March 31, 2024, and March 31, 2023. All financial information contained in this news release is qualified in its entirety with reference to such financial statements. To the extent that the financial information contained in this news release is inconsistent with the information contained in the Company's audited financial statements, the financial information contained in this news release shall be deemed to be modified or superseded by the Company's audited financial statements. The making of a modifying or superseding statement shall not be deemed an admission for any purposes that the modified or superseded statement, when made, constituted a misrepresentation for purposes of applicable securities laws.
GOODNESS GROWTH HOLDINGS, INC. | |||||||
CONSOLIDATED BALANCE SHEETS AS OF 3/31/2024 AND 12/31/2023 | |||||||
(Amounts Expressed in United States Dollars, Unaudited and Condensed) | |||||||
March 31, | December 31, | ||||||
2024 | 2023 | ||||||
Assets | |||||||
Current assets: | |||||||
Cash | $ | 12,603,903 | $ | 15,964,665 | |||
Accounts receivable, net of allowance for doubtful accounts of $254,961 and $453,860, respectively | 2,753,673 | 3,086,640 | |||||
Income tax receivable | 12,102,916 | 12,278,119 | |||||
Inventory | 19,357,250 | 19,285,870 | |||||
Prepayments and other current assets | 1,046,127 | 1,336,234 | |||||
Notes receivable, current | 3,750,000 | 3,750,000 | |||||
Warrants held | 3,265,231 | 1,937,352 | |||||
Assets Held for Sale | 92,297,445 | 91,213,271 | |||||
Total current assets | 147,176,545 | 148,852,151 | |||||
Property and equipment, net | 23,541,445 | 23,291,183 | |||||
Operating lease, right-of-use asset | 11,118,882 | 2,018,163 | |||||
Intangible assets, net | 8,513,765 | 8,718,577 | |||||
Deposits | 533,745 | 383,645 | |||||
Total assets | $ | 190,884,382 | $ | 183,263,719 | |||
Liabilities | |||||||
Current liabilities | |||||||
Accounts Payable and Accrued liabilities | $ | 7,970,158 | $ | 7,674,389 | |||
Long-Term debt, current portion | 60,896,288 | 60,220,535 | |||||
Right of use liability | 882,457 | 890,013 | |||||
Uncertain tax liability | 26,116,000 | 22,356,000 | |||||
Liabilities held for sale | 88,373,080 | 88,326,323 | |||||
Total current liabilities | 184,237,983 | 179,467,260 | |||||
Right-of-use liability | 19,635,409 | 10,543,934 | |||||
Other long-term liabilities | 176,257 | 155,917 | |||||
Convertible debt, net | 9,410,053 | 9,140,257 | |||||
Total liabilities | $ | 213,459,702 | 199,307,368 | ||||
Stockholders' equity (deficiency) | |||||||
Subordinate Voting Shares ($- par value, unlimited shares authorized; 111,041,230 shares issued and outstanding at March 31, 2024 and 110,007,030 at December 31, 2023) | — | — | |||||
Multiple Voting Shares ($- par value, unlimited shares authorized; 320,851 shares issued and outstanding at March 31, 2024 and 331,193 at December 31, 2023) | — | — | |||||
Super Voting Shares ($- par value; unlimited shares authorized; 0 shares issued and outstanding at March 31, 2024 and December 31, 2023) | — | — | |||||
Additional Paid in Capital | 187,564,192 | 187,384,403 | |||||
Accumulated deficit | (210,139,512 | ) | (203,428,052 | ) | |||
Total stockholders' equity (deficiency) | $ | (22,575,320 | ) | $ | (16,043,649 | ) | |
Total liabilities and stockholders' equity (deficiency) | $ | 190,884,382 | $ | 183,263,719 | |||
GOODNESS GROWTH HOLDINGS, INC. | ||||||||
CONSOLIDATED STATEMENTS OF OPERATIONS | ||||||||
THREE MONTHS ENDED MARCH 31, 2024 AND 2023 | ||||||||
(Amounts Expressed in United States Dollars, Unaudited and Condensed) | ||||||||
Three Months Ended | ||||||||
March 31, | ||||||||
2024 | 2023 | |||||||
Revenue | $ | 24,087,315 | $ | 19,088,423 | ||||
Cost of sales | ||||||||
Product costs | 12,146,888 | 9,578,211 | ||||||
Inventory valuation adjustments | (304,000 | ) | (10,000 | ) | ||||
Gross profit | 12,244,427 | 9,520,212 | ||||||
Operating expenses: | ||||||||
Selling, general and administrative | 7,051,613 | 7,156,835 | ||||||
Stock-based compensation expenses | 179,789 | 1,675,594 | ||||||
Depreciation | 73,547 | 159,511 | ||||||
Amortization | 180,034 | 159,766 | ||||||
Total operating expenses | 7,484,983 | 9,151,706 | ||||||
Gain (loss) from operations | 4,759,444 | 368,506 | ||||||
Other income (expense): | ||||||||
Impairment of long-lived assets | — | — | ||||||
Gain (loss) on disposal of assets | (120,856 | ) | — | |||||
Gain (loss) on sale of property and equipment | — | — | ||||||
Interest expenses, net | (8,722,637 | ) | (7,134,789 | ) | ||||
Other income (expenses) | 1,317,589 | 22,313 | ||||||
Other income (expenses), net | (7,525,904 | ) | (7,112,476 | ) | ||||
Loss before income taxes | (2,766,460 | ) | (6,743,970 | ) | ||||
Current income tax expenses | (3,945,000 | ) | (1,725,000 | ) | ||||
Deferred income tax recoveries | — | 63,000 | ||||||
Net loss and comprehensive loss | (6,711,460 | ) | (8,405,970 | ) | ||||
Net loss per share - basic and diluted | $ | (0.05 | ) | $ | (0.07 | ) | ||
Weighted average shares used in computation of net loss per share - basic & diluted | 143,126,330 | 128,126,330 | ||||||
GOODNESS GROWTH HOLDINGS, INC. | ||||||||
CONSOLIDATED STATEMENTS OF CASH FLOWS | ||||||||
THREE MONTHS ENDED MARCH 31, 2024 AND 2023 | ||||||||
(Amounts Expressed in United States Dollars, Unaudited and Condensed) | ||||||||
March 31, | ||||||||
2024 | 2023 | |||||||
CASH FLOWS FROM OPERATING ACTIVITIES | ||||||||
Net loss | $ | (6,711,460 | ) | $ | (8,405,970 | ) | ||
Adjustments to reconcile net loss to net cash used in operating activities: | ||||||||
Inventory valuation adjustments | (304,000 | ) | (10,000 | ) | ||||
Depreciation | 73,547 | 159,511 | ||||||
Depreciation capitalized into inventory | 560,180 | 734,087 | ||||||
Non-cash operating lease expense | 103,564 | 206,290 | ||||||
Amortization of intangible assets | 180,034 | 159,766 | ||||||
Amortization of intangible assets capitalized into inventory | 24,778 | — | ||||||
Stock-based payments | 179,789 | 1,675,594 | ||||||
Warrants held | (1,327,879 | ) | — | |||||
Interest Expense | 2,015,889 | 1,398,848 | ||||||
Impairment of long-lived assets | — | — | ||||||
Deferred income tax | — | (63,000 | ) | |||||
Accretion | 52,815 | 394,573 | ||||||
Loss (gain) on disposal of assets | 120,856 | — | ||||||
Change in operating assets and liabilities: | ||||||||
Accounts Receivable | 348,817 | 24,448 | ||||||
Prepaid expenses | 290,106 | 513,902 | ||||||
Inventory | 299,252 | (1,230,547 | ) | |||||
Income taxes | 175,203 | 1,807,364 | ||||||
Uncertain tax position liabilities | 3,760,000 | — | ||||||
Accounts payable and accrued liabilities | 174,340 | (1,141,057 | ) | |||||
Changes in operating lease liabilities | (168,746 | ) | — | |||||
Change in assets and liabilities held for sale | (1,037,417 | ) | (18,767 | ) | ||||
Net cash provided by (used in) operating activities | (1,190,332 | ) | (3,794,958 | ) | ||||
CASH FLOWS FROM INVESTING ACTIVITIES | ||||||||
PP&E Additions | (899,264 | ) | (197,827 | ) | ||||
Deposits | (150,100 | ) | (522,375 | ) | ||||
Net cash provided by (used in) investing activities | (1,049,364 | ) | (720,202 | ) | ||||
CASH FLOWS FROM FINANCING ACTIVITIES | ||||||||
Debt principal payments | (1,050,000 | ) | — | |||||
Lease principal payments | (71,066 | ) | (288,574 | ) | ||||
Net cash provided by (used in) financing activities | (1,121,066 | ) | (288,574 | ) | ||||
Net change in cash | (3,360,762 | ) | (4,803,734 | ) | ||||
Cash, beginning of period | 15,964,665 | 15,149,333 | ||||||
Cash, end of period | $ | 12,603,903 | $ | 10,345,599 | ||||
GOODNESS GROWTH HOLDINGS, INC. STATE-BY-STATE REVENUE PERFORMANCE THREE MONTHS ENDED MARCH 31, 2024 AND 2023 | |||||||||||||||
Three Months Ended | |||||||||||||||
March 31, | |||||||||||||||
2024 | 2023 | $ Change | % Change | ||||||||||||
Retail: | |||||||||||||||
MN | $ | 10,977,089 | $ | 10,718,916 | $ | 258,173 | 2 | % | |||||||
NY | 1,821,269 | 2,361,942 | (540,673 | ) | (23 | )% | |||||||||
NM | — | 1,052,316 | (1,052,316 | ) | (100 | )% | |||||||||
MD | 6,801,082 | 2,338,625 | 4,462,457 | 191 | % | ||||||||||
Total Retail | $ | 19,599,440 | $ | 16,471,799 | $ | 3,127,641 | 19 | % | |||||||
Wholesale: | |||||||||||||||
MD | 3,353,661 | 1,563,875 | 1,789,786 | 114 | % | ||||||||||
NY | 1,134,214 | 1,052,749 | 81,465 | 8 | % | ||||||||||
Total Wholesale | $ | 4,487,875 | $ | 2,616,624 | $ | 1,871,251 | 72 | % | |||||||
Total Revenue | $ | 24,087,315 | $ | 19,088,423 | $ | 4,998,892 | 26 | % | |||||||
NY and NM Revenue | $ | (2,955,483 | ) | $ | (4,467,007 | ) | $ | 1,511,524 | (34 | )% | |||||
Total Revenue excluding NY and NM | $ | 21,131,832 | $ | 14,621,416 | $ | 6,510,416 | 45 | % | |||||||
Reconciliation of Non-GAAP Financial Measures
Goodness Growth management occasionally elects to provide certain non-GAAP financial measures such as Earnings Before Interest, Taxes, Depreciation and Amortization (EBITDA). EBITDA is a non-GAAP measure and does not have a standardized definition under GAAP. The following information provides reconciliations of the supplemental non-GAAP financial measures, presented herein to the most directly comparable financial measures calculated and presented in accordance with GAAP. The Company has provided the non-GAAP financial measures, which are not calculated or presented in accordance with GAAP, as supplemental information and in addition to the financial measures that are calculated and presented in accordance with GAAP. These supplemental non-GAAP financial measures should not be considered superior to, as a substitute for or as an alternative to, and should be considered in conjunction with, the GAAP financial measures presented.
Reconciliation of Net Loss to EBITDA 1 | ||||||||
Three Months Ended | ||||||||
March 31, | ||||||||
2024 | 2023 | |||||||
Net income (loss) | $ | (6,711,460 | ) | $ | (8,405,970 | ) | ||
Interest expense, net | 8,722,637 | 7,134,789 | ||||||
Income taxes | 3,945,000 | 1,662,000 | ||||||
Depreciation & Amortization | 253,581 | 319,277 | ||||||
Depreciation included in cost of goods sold | 584,958 | 734,087 | ||||||
EBITDA (non-GAAP) | $ | 6,794,716 | $ | 1,444,183 | ||||
1 1Q24 EBITDA includes a $1.3 million gain on Grown Rogue warrants which are marked to market at each period end | ||||||||
News Provided by GlobeNewswire via QuoteMedia
Trulieve Cannabis Corp. (CSE: TRUL ) (OTCQX: TCNNF ) ("Trulieve" or "the Company"), a leading and top-performing cannabis company in the U.S., today announced planned event participation in May.
Information about our events, links to events where available, and slide presentations can be found at: https://investors.trulieve.com/events
About Trulieve
Trulieve is an industry leading, vertically integrated cannabis company and multi-state operator in the U.S., with leading market positions in Arizona , Florida , and Pennsylvania . Trulieve is poised for accelerated growth and expansion, building scale in retail and distribution in new and existing markets through its hub strategy. By providing innovative, high-quality products across its brand portfolio, Trulieve delivers optimal customer experiences and increases access to cannabis, helping patients and customers to live without limits. Trulieve is listed on the CSE under the symbol TRUL and trades on the OTCQX market under the symbol TCNNF. For more information, please visit Trulieve.com.
Facebook: @Trulieve
Instagram: @Trulieve _
X: @Trulieve
Investor Contact
Christine Hersey , Vice President of Investor Relations
+1 (424) 202-0210
Christine.Hersey@Trulieve.com
Media Contact
Phil Buck , APR, Corporate Communications Manager
+1 (406) 370-6226
Philip.Buck@Trulieve.com
View original content to download multimedia: https://www.prnewswire.com/news-releases/trulieve-announces-may-2024-event-participation-302137377.html
SOURCE Trulieve Cannabis Corp.
View original content to download multimedia: http://www.newswire.ca/en/releases/archive/May2024/07/c6835.html
News Provided by Canada Newswire via QuoteMedia
Cronos Group Inc. (NASDAQ: CRON) (TSX: CRON) ("Cronos" or the "Company") announced today that it is expanding its medical brand, PEACE NATURALS, into the United Kingdom market with its first shipment of cannabis flower to GROW ® Pharma, a leading distributor of prescribed medicinal cannabis products in the UK.
Cronos will provide high-quality premium cannabis products, which have become synonymous globally with the PEACE NATURALS® brand, to patients in the UK through this partnership. The Company's investments in R&D, tissue culture, and its cannabis genetics breeding program have enabled it to expand to Germany and Australia in the past year.
"Supplying the UK market, which we think has the potential to grow significantly this year, is another milestone for Cronos as we enter and expand within international markets," said Mike Gorenstein, Chairman, President, and CEO, Cronos. "We intend to establish PEACE NATURALS ® as a top brand in the UK, as we have done in Israel and Germany. We will continue to push forward on new market growth opportunities and expand our portfolio of borderless products while growing our European footprint."
Grow Pharma works with UK-based clinics as a wholesaler and pharmacy distributor as well as directly with patients by handling prescriptions and delivering products by mail. Their focus on quality of the supply chain, breadth of their portfolio and delivery of the best service to patients support their strong position as one of the market leaders.
"We're proud and excited to partner with Cronos and to further expand our offering to UK patients with high-quality medical cannabis products," said Pierre van Weperen, CEO, Grow Pharma. "As demand continues to increase and the expectations for high quality medical products are shifting upwards across the UK, we're pleased about this new partnership and to be able to supply PEACE NATURALS ® medical cannabis products to patients."
About Cronos Group Inc.
Cronos is an innovative global cannabinoid company committed to building disruptive intellectual property by advancing cannabis research, technology and product development. With a passion to responsibly elevate the consumer experience, Cronos is building an iconic brand portfolio. Cronos' diverse international brand portfolio includes Spinach ® , PEACE NATURALS ® and Lord Jones ® . For more information about Cronos and its brands, please visit: thecronosgroup.com.
Forward-looking Statements
This press release may contain information that may constitute "forward-looking information" or "forward-looking statements" within the meaning of applicable Canadian and U.S. securities laws and court decisions (collectively, "Forward-looking Statements"). All information contained herein that is not clearly historical in nature may constitute Forward-looking Statements. In some cases, Forward-looking Statements can be identified by the use of forward-looking terminology such as "may", "will", "expect", "plan", "anticipate", "intend", "potential", "estimate", "believe" or the negative of these terms, or other similar expressions intended to identify Forward-looking Statements. Some of the Forward-looking Statements contained in this press release include statements about the Company's plans to supply cannabis for GROW ® Pharma, the Company's plans with respect to international market entrance and expansion, the Company's partnership with GROW ® Pharma and impact of such partnership on GROW ® Pharma products, market share and competitive positioning, anticipated growth in the UK market, growth of demand in the UK market, consumer expectations for medicinal cannabis products in the UK, the Company's intent to establish its PEACE NATURALS ® brand as a top brand for patients in the UK, and Cronos' intention to build an international iconic brand portfolio and develop disruptive intellectual property. Forward-looking Statements are necessarily based upon a number of estimates and assumptions that, while considered reasonable by management, are inherently subject to significant business, economic and competitive risks, financial results, results, performance or achievements expressed or implied by those Forward-looking Statements and the Forward-looking Statements are not guarantees of future performance. A discussion of some of the material risks applicable to the Company can be found in the Company's Annual Report on Form 10-K for the year ended December 31, 2023 , which has been filed on SEDAR and EDGAR and can be accessed at www.sedar.com and www.sec.gov/edgar , respectively. Any Forward-looking Statement included in this press release is made as of the date of this press release and, except as required by law, Cronos disclaims any obligation to update or revise any Forward-looking Statement. Readers are cautioned not to put undue reliance on any Forward-looking Statement.
For further information, please contact:
Investor Relations Contact:
Shayne Laidlaw
Investor Relations
Tel: (416) 504-0004
investor.relations@thecronosgroup.com
Media Relations Contact:
Emily Whalen
Communications
Tel: (416) 504-0004
media.relations@thecronosgroup.com
News Provided by GlobeNewswire via QuoteMedia
Since the legalisation of medical cannabis in 2016, Australia has been steadily developing its marijuana industry — and it’s been attracting attention from international players and investors.
With a quickly growing population of over 27 million people and a robust agricultural industry, the country could be positioned to mould itself into a major force in the international cannabis space.
Here the Investing News Network takes a look at how the cannabis industry in Australia has been shaping up since legalisation. Read on to see what you need to know about investing in cannabis down under.
As mentioned, Australia’s parliament passed legislation to allow the cultivation of cannabis for medicinal and research purposes in 2016 by amending the Narcotic Drugs Act 1967. Cannabis companies have been cropping up since then.
While the cannabis industry is still young, Australia’s agricultural sector is well established — in fact, it's one of the largest contributors to the nation's GDP. According to the Australian Bureau of Agricultural and Resource Economics and Sciences, the country's agriculture output was valued at AU$80 billion in the 2023 to 2024 period, with forecasted growth of 6 percent for the 2024 to 2025 period. Australia's agriculture export prowess means it may be able to capitalise on the trend of moving medical marijuana products internationally.
Recreational cannabis use isn’t legal in most parts of Australia. The exception is the Australian Capital Territory, which in early 2020 made it legal to grow, possess and personally use small amounts of cannabis. That said, the Australian Institute of Health and Welfare identifies cannabis as the most widely used illicit drug in the country.
A 2019 research study states that at the time more than 40 percent of Australians in were in favour of legalising marijuana entirely. More recently, a 2023 survey showed that 50 percent of Australians supported legalising the right to own six personal cannabis plants, with only 31 percent of those surveyed opposing such a law.
Medical cannabis is overseen by the Office of Drug Control, which issues three types of licences: research, manufacturing of a drug or product and cultivation or production of medical cannabis. As of January 2024, 48 cannabis cultivation or production licences and 27 manufacturing licences were held by medical cannabis companies in Australia.
Medical cannabis users face some difficulties when it comes to accessing the drug. Patients can only receive medicinal cannabis products via a specialist and then may have to wait up to a month for government approval. Still, a 2021 survey of medical cannabis users showed that legal medical cannabis use is on the rise in the country; 37 percent of respondents had a legal prescription for cannabis compared to just 2.5 percent in 2018.
Australia's cannabis space is still in its early stages and hasn't hit its peak. More cannabis stocks are expected to list on the Australian Securities Exchange (ASX) in the future, which means more investment opportunities.
Elixinol Wellness (ASX:EXL,OTC Pink:ELLXF) was formed in 2018, when Colorado-based Elixinol partnered up with Hemp Food Australia to form an international brand and launch an initial public offering.
While Hemp Food Australia manufactures and distributes hemp food and skincare products, Elixinol is a retail provider on the CBD side of things, with dietary supplements and topical cannabis products. Elixinol has focused on building a solid global footprint with operations in the Americas, Europe and Asia.
In its latest quarterly report, Elixinol reported improvements to group revenues, which were up 76 percent from the same period last year for a total of AU$3 million. Australian brand revenues came to AU$2.5 million, up 140 percent.
Elixinol completed its acquisition of Ananda Food in early 2024, further solidifying its strong position in the Australian hemp market, while adding complementary products to its range of offerings.
Another big player in the budding Australian cannabis space is Cann Group (ASX:CAN,OTC Pink:CNGGF). Established in 2014, Cann Group was the first cannabis company to be issued a cannabis research licence and the first to be granted a medical cannabis cultivation licence by the Australian government.
The company has since worked to develop and supply cannabis, cannabis resin and medical cannabis products to patients for everything from multiple sclerosis to chronic pain. It does so using its own dry cannabis flower, which puts it ahead of the pack in a market that is still largely driven by imports. Cann Group has the capacity to produce 12,500 kilograms per year of dry cannabis flower for international and domestic medical cannabis markets at its Mildura growing facility in Victoria, which it completed in 2022 with support from the National Australia Bank.
There is also Althea Group (ASX:AGH), a producer, supplier and exporter of pharmaceutical-grade medicinal marijuana; it received its licence to cultivate medical cannabis in 2018. Currently, the company operates in regulated medical cannabis markets, including Australia and the UK. In late 2020, it received approval to sell cannabis products in Germany. The approval made Althea Germany’s first commercial supplier of made-in-Australia medical cannabis products. The German medical cannabis market is expected to be worth approximately AU$594.8 billion by 2029, as per Statista.
For the first three quarters of its 2024 fiscal year, Althea reported a record AU$26.6 million in cash receipts, with AU$8.4 million (AU$4.2 million each from recreational and medicinal) in the quarter ended on March 31.
Some of the largest names in Canada’s cannabis landscape, such as Canopy Growth (NYSE:CGC,TSX:WEED) and Aurora Cannabis (NYSE:ACB,TSX:ACB), have operations in the region as well.
In 2018, Canopy launched Spectrum Cannabis Australia, a medical cannabis company. Now called Spectrum Therapeutics, the company, which remains a subsidiary of Canopy, states it is developing "innovative cannabis-based products to create a range of effective formulations and delivery mechanisms and research their therapeutic effects."
Aurora has a partnership with MedReleaf Australia, a pharmaceutical cannabis company, and together they provide Aurora's products using their MedReleaf Concession Scheme. The program supports "those with Pensioner Concession Cards, Commonwealth Seniors Health Cards, Health Care Cards, and Veterans Cards" and offers compassionate pricing.
Further offerings are coming to Australia from Aurora Cannabis, the company announced in late April, including a new range of premium dried flower products.
According to Future Market Insights, Australia's legal cannabis market — a category that includes medical cannabis and hemp products — is projected to experience a CAGR of 30.1 percent into 2033 to reach US$828.2 million in revenue.
Alongside the legalisation of medical cannabis was the legalisation of overseas exports in 2018, and Australia had big plans for the growth of its international presence at the time. “We’d like to be potentially the world’s number one supplier,” said Australian Health Minister Greg Hunt on a local radio station that year. This has yet to come to pass; the 10 largest cannabis companies are all located in either Canada or the US.
There has been talk about the legalisation of cannabis for recreational use in response to growing support for complete cannabis legalisation across the country. In August 2023, a senator put forth the first federal cannabis legalisation bill in Australia, called the Legalising Cannabis Act 2023.
According to the bill's summary, if passed, it would establish "the Cannabis Australia National Agency as a statutory agency to register cannabis strains and regulate activities relating to cannabis including: growing and possessing cannabis plants; manufacturing and selling cannabis products; operating cannabis cafes; and importing and exporting cannabis products." There will be a public hearing for the bill on May 31.
Overall, the growth of the country’s medical cannabis industry — and the Australian marijuana companies that exist within it — is a growing opportunity. While recreational cannabis remains illegal, moving forward investors should keep an eye out for updates on the Legalising Cannabis Act 2023.
This is an updated version of an article first published by the Investing News Network in 2019.
Don’t forget to follow us @INN_Australia for real-time news updates!
Securities Disclosure: I, Melissa Pistilli, hold no direct investment interest in any company mentioned in this article.
April was a game-changer for the cannabis industry.
After deliberating for almost five months, the Drug Enforcement Administration moved to reschedule cannabis as lawmakers worked to combine the SAFER Banking Act with newly introduced stablecoin legislation.
Meanwhile, controversy struck as legal cannabis was seized in New Mexico, Canada's Federal Budget 2024 was released with no mention of reform to high excise tax rates, and the saga of a once high-end cannabis dispensary finally ended in bankruptcy.
Keep reading to discover more about these industry-shaping events.
Marijuana Moment reported on Tuesday (April 30) that Attorney General Merrick Garland had submitted to the White House Office of Management and Budget a proposal to reschedule cannabis from a Schedule I substance, the same category as heroin and methamphetamines, to a Schedule III one.
The Department of Health and Human Services suggested cannabis be reclassified on August 29, 2023, and the DEA has been deliberating on the decision for months, urged by lawmakers to heed the recommendation. President Biden has been vocal about his stance on this issue and has pressed the Attorney General to expedite the process, suggesting his readiness to move forward once the proposal reaches his desk.
While the most recent development is a promising step in the right direction, it's worth noting that rescheduling could still take months. It will be subject to a public comment period before it can be sent to the Federal Register for publication, and Congress could still overturn the rule under the Congressional Review Act, which would send the matter to the Senate for a vote.
MedMen (CSE:MMEN,OTCQB:MMNFF), the first cannabis company in California to achieve a US$1 billion valuation, filed for bankruptcy in Canada on April 26. Its subsidiary company, based in Los Angeles, has been placed in receivership.
According to findings provided by multiple sources, the company, which has been struggling since 2020, is in roughly US$410.4 million of debt. Several poor decisions have been cited as the reason for its downfall, including opening a cannabis store on New York’s lavish Fifth Avenue before the state legalized cannabis. MedMen has also been hit with multiple lawsuits over the years, both from employees who accuse the company of violating labor laws and from investors who alleged excessive spending, stock price manipulation and bank fraud. The company had been selling off assets to try and make a profit since 2022.
In early 2024, the OTC marketplace designated MedMen's securities to the Expert Market, thereby restricting its stock quote from public view. The marketplace cited failure to adhere to its reporting obligations as the reason for its decision.
The SAFER Banking Act, which would prevent the federal government from taking action against banks and insurance companies doing business with legal cannabis companies, is garnering renewed support as lawmakers push for its potential inclusion in a broader package combining cannabis banking and stablecoin regulation.
Senate Banking Committee Chairman Sherrod Brown said on April 16 that he would be open to advancing stablecoin legislation if it is part of a package that includes the SAFER Banking Act, a measure that has won bipartisan approval in the Senate Banking Committee but has yet to receive full Senate approval. SAFER was passed by the Senate Banking Committee in a 14-9 vote on September 27 but has yet to be considered on the floor.
Lawmakers are reportedly hoping to attach a package that combines the SAFER Banking Act and a stablecoin bill to the reauthorization of the Federal Aviation Administration (FAA), which is scheduled to pass by May 10, although the plan has some opposition. The Lummis-Gillibrand Payment Stablecoin Act, which has gained bipartisan support, could be the most likely contender.
The plan has the support of House Financial Services Committee member Maxine Waters, who has been working with Committee Chairman Patrick McHenry to pass stablecoin legislation. She has also discussed the potential package deal with both Brown and Senate Majority Leader Chuck Schumer, a driving force behind the SAFER Banking Act. During an interview with Bloomberg, Waters said she was optimistic that stablecoin legislation would be passed soon, and that she was supportive of cannabis banking legislation as well.
Republican Representative French Hill also told Bloomberg he would vote in favor of tying cannabis banking to stablecoin legislation.
However, Senate Republican leader Mitch McConnell, who has blocked the SAFER Act in the past, has signaled he will continue to block cannabis banking legislation, and House Speaker Mike Johnson has said he opposes fast-tracking “unrelated measures” to such a critical piece of legislation as the FAA, according to sources for Bloomberg.
While this may mean it's unlikely the package will go forward with the FAA legislation, Schumer is not giving up.
“There are lots of people who have different amendments not relevant to the FAA that want to get them on. I’m one of those—but we have to get this done in a bipartisan way. And we’ll figure out the best way to get it done,” he told Marijuana Moment.
If the bills fail to advance, the SAFER Banking Act could move forward as a standalone bill, with no date set to hold it to a vote, or lawmakers may try to attach it to another bill following the elections in November.
Despite legislative support from the Kansas State House and senators such as Rob Olson, a proposal to dislodge Senate Bill 135, also known as the Medical Cannabis Regulation Act, from the Senate Federal and State Affairs Committee and bring it to the Senate floor was unsuccessful on April 29.
The new motion to transfer the bill to the Senate came to a vote in the Republican-controlled Kansas state Senate, but it only received 12 out of the 24 votes it needed to move forward. The results of the vote ultimately killed the bill, leaving Kansas one of the few states that have yet to legalize medical cannabis despite years of attempts.
SB 135 would have allowed for the cultivation, processing, distribution, sale and use of medical cannabis for patients with qualifying conditions. Conditions named in the bill included Alzheimer’s disease, cancer, epilepsy or other seizure disorders, Parkinson’s disease, Tourette’s syndrome, fibromyalgia and “pain that is either chronic and severe or intractable.”
The bill had been tabled by Senate Republicans on March 17 of last year after two successful hearings.
Canada’s government released its 2024 Federal Budget on April 16, and the contents disappointed hopeful cannabis operators across the country. Despite ongoing campaigns by Canadian operators calling for reform to the excise tax, the budget failed to address the issue, leaving the industry without the relief it has been seeking for years.
The current cannabis excise tax rate in Canada, which imposes C$1 per gram of cannabis or 10 percent of the producer’s selling price – whichever is higher – has significantly burdened the industry. High rates on sales over C$10 have impacted the profitability of the legal cannabis business, forcing operators to drive up the prices and driving consumers to the illicit market. This challenging financial environment has made it difficult for Canadian operators to expand, causing a stifled market with only a handful of major competitors.
For example, in August 2023, Tantalus Labs, a British Columbia-based company, was acquired by Atlantic Cultivation following insolvency. This came after the Canadian Revenue Agency (CRA) refused to renew Tantalus Labs’ tax license due to unpaid excise taxes amounting to C$4.3 million, part of a total C$14 million debt. Facing the CRA’s threat to destroy more than 1,200 kilograms of cannabis, Tantalus Labs conducted a court-approved fire sale of its remaining inventory to recover funds for creditors; however, it brought in only a fraction of what regular sales would have.
Despite recommendations from a government-appointed panel of experts to reconsider how excise tax rates are applied and a direct warning from Canada’s Tax Policy Branch to Canadian Finance Minister Chrystia Freeland that the excise tax was hurting Canadian companies, there was almost no mention of the cannabis industry in the 430 page budget document. The Federal government also increased eight cannabis regulatory fees on April 1.
Curaleaf Holdings (TSX:CURA,OTCQX:TSNDF), a major US-based cannabis operator that is publicly listed on the Toronto Stock Exchange, completed its acquisition of Canadian cannabis producer Northern Green Canada on April 23. Northern Green Canada is one of the few Canadian brands with a presence in Europe, having secured Good Manufacturing Practice certification (GMP) from the European Union in August 2022.
“This is an incredibly important deal for our international expansion strategy, as we’ll be able to bolster our supply of high-quality EU-GMP certified flowers immediately to key European markets as well as enter the fast-growing markets of Australia and New Zealand,” Boris Jordan, founder and executive chairman of Curaleaf, said in a press release.
According to the terms of the deal, which was announced in March, Curaleaf provided an initial payment of subordinate voting shares valued at US$16 million. An earnout is set to be paid in 2025 based on Northern Green Canada’s performance. Half of the earnout sum will be paid in cash and half in voting shares.
There have been six incidents of US Customs and Border Protection (CBP) officials intercepting state-regulated cannabis reported by licensed operators in New Mexico between February 14 and April 18, according to an article by MJBizDaily. State documents shared with the outlet show that the officials seized product amounting to at least 70 pounds of cannabis flower, concentrates, edibles, vape pens, cartridges and lab-bound samples.
The documents also show that the drivers had been detained for up to two and a half hours, that a K-9 unit was used on a vehicle transporting cannabis at least once and that one driver was told he would be placed under arrest and prosecuted by the DEA.
No similar incidents have been reported at other southern border crossings or in neighboring states.
In a letter sent to New Mexico Senator Mark Heinrich, managing partner of Las Cruces-based Head Space Distribution Kai Kirk said that product losses have amounted to almost US$300,000 and that seizures are threatening the “burgeoning cannabis industry and economic opportunity in New Mexico.” He also stated that in many cases drivers have had their fingerprints taken and during an arrest, the arresting officer failed to read the driver his Miranda rights.
New Mexico’s proximity to the southern border makes it a hotspot for border security and immigration enforcement, resulting in a larger presence of federal agents in the state. Federal agents, who are required to enforce federal drug laws, create challenges for local businesses that operate within state laws but are still in conflict with federal regulations. A CBP spokesperson told MJBizDaily that since cannabis is still a Schedule 1 substance, “any federal officer will take appropriate actions” if they encounter it during a search.
If the DEA cannabis rescheduling process is successful, it would likely alleviate the issues faced by New Mexico’s cannabis industry due to the conflicting state and federal laws. In the meantime, industry stakeholders like Kirk continue to advocate for a resolution that balances the enforcement of federal laws with the rights of legal cannabis operators in the state.
In his letter, which was co-signed by the Cannabis Chamber of Commerce and several dispensaries, delivery personnel and cultivators, Kirk requests that the border patrol policy be updated to reflect the state-legal nature of cannabis products and that either any product seized be returned or that operators be monetarily compensated.
Don’t forget to follow us @INN_Cannabis for real-time news updates!
Securities Disclosure: I, Meagen Seatter, hold no direct investment interest in any company mentioned in this article.
Filing reflects Company's belief that Verano's defense against claims of unlawful conduct is without merit –
– Legal filing represents a documentary record and corresponding damages analysis –
MINNEAPOLIS, May 02, 2024 (GLOBE NEWSWIRE) -- Goodness Growth Holdings, Inc. ("Goodness Growth" or the "Company") (CSE: GDNS; OTCQX: GDNSF), today announced that it has filed an application with the Supreme Court of British Columbia for summary determination in its ongoing litigation with Verano Holdings, Inc. ("Verano") related to Verano's wrongful termination of the share exchange agreement (the "Arrangement Agreement") between the parties pursuant to which Verano agreed to acquire all of the outstanding capital stock of Goodness Growth in a transaction announced on February 1, 2022. The application filing for summary determination is a public document available through the registry of the Supreme Court of British Columbia.
As previously disclosed, on October 14, 2022, Verano delivered a Notice of Termination of the Arrangement Agreement to Goodness Growth. Goodness Growth subsequently filed a notice of civil claim against Verano with the Supreme Court of British Columbia on October 21, 2022. Goodness Growth is seeking substantial damages, specifically US $860.9 million, as well as other costs and legal fees, based on Verano's breach of contract and of its duty of good faith and honest performance. While the Company's filing of its application for summary determination reflects its belief that Verano's defense against its claims of unlawful conduct is without merit, Goodness Growth can make no assurances regarding the expected timeframe to resolve this litigation, or its ability to recover damages from Verano.
Chief Executive Officer Josh Rosen commented, "I stepped into my role at a vulnerable time for Goodness Growth, in the aftermath of Verano's termination of our merger agreement. As I have said before, we view this litigation as a valuable asset of Goodness Growth. Our filing today reflects our ongoing commitment to protecting and realizing it. The transaction with Verano was anticipated to be transformative: it was going to provide Goodness Growth with a means of unlocking its potential, including in the key markets of New York and Minnesota. We are committed to pursuing Verano for what we believe was a calculated and wrongful termination that deprived Goodness Growth of both access to capital and operational improvements. Our filing today represents the careful culmination of months of work: to compile what we consider to be a clear documentary record of what occurred, and corresponding damages analysis. On the latter front, the math speaks for itself. We're hopeful for an early determination, and an outcome reflective of the record and the math."
About Vireo & Goodness Growth
Vireo (Goodness Growth) was founded as a pioneer in medical cannabis in 2014 and sustained with an entrepreneurial drive that fuels our ongoing commitment to serve and delight our key stakeholders, most notably our customers, our employees, our shareholders, our industry collaborators, and the communities in which we live and operate. We work every day to get better and our team prioritizes 1) empowering and supporting strong local market leaders and 2) strategic, prudent capital and human resource allocation. For more information, please visit www.vireohealth.com .
Contact Information
Investor Inquiries: Sam Gibbons Managing Director sam.gibbons@alpha-ir.com (612) 314-8995 | Media Inquiries: Amanda Hutcheson Senior Manager, Communications amandahutcheson@goodnessgrowth.com (919) 815-1476 |
Forward-Looking Statement Disclosure
This press release contains "forward-looking information" within the meaning of applicable United States and Canadian securities legislation. To the extent any forward-looking information in this press release constitutes "financial outlooks" within the meaning of applicable United States or Canadian securities laws, this information is being provided as preliminary financial results; the reader is cautioned that this information may not be appropriate for any other purpose and the reader should not place undue reliance on such financial outlooks. Forward-looking information contained in this press release may be identified by the use of words such as "should," "believe," "estimate," "would," "looking forward," "may," "continue," "expect," "expected," "will," "likely," "subject to," "transformation," and "pending," variations of such words and phrases, or any statements or clauses containing verbs in any future tense. These statements should not be read as guarantees of future performance or results. Forward-looking information includes both known and unknown risks, uncertainties, and other factors which may cause the actual results, performance, or achievements of the Company or its subsidiaries to be materially different from any future results, performance, or achievements expressed or implied by the forward-looking statements or information contained in this press release. Financial outlooks, as with forward-looking information generally, are, without limitation, based on the assumptions and subject to various risks as set out herein and in our Annual Report on Form 10-K filed with the Securities Exchange Commission. Our actual financial position and results of operations may differ materially from management's current expectations and, as a result, our revenue, EBITDA, and cash on hand may differ materially from the values provided in this press release. Forward-looking information is based upon a number of estimates and assumptions of management, believed but not certain to be reasonable, in light of management's experience and perception of trends, current conditions, and expected developments, as well as other factors relevant in the circumstances, including assumptions in respect of current and future market conditions, the current and future regulatory environment, and the availability of licenses, approvals and permits.
Although the Company believes that the expectations and assumptions on which such forward-looking information is based are reasonable, the reader should not place undue reliance on the forward-looking information because the Company can give no assurance that they will prove to be correct. Actual results and developments may differ materially from those contemplated by these statements. Forward-looking information is subject to a variety of risks and uncertainties that could cause actual events or results to differ materially from those projected in the forward-looking information. Such risks and uncertainties include, but are not limited to: risks related to the timing and content of adult-use legislation in markets where the Company currently operates; current and future market conditions, including the market price of the subordinate voting shares of the Company; risks related to epidemics and pandemics; federal, state, local, and foreign government laws, rules, and regulations, including federal and state laws and regulations in the United States relating to cannabis operations in the United States and any changes to such laws or regulations; operational, regulatory and other risks; execution of business strategy; management of growth; difficulties inherent in forecasting future events; conflicts of interest; risks inherent in an agricultural business; risks inherent in a manufacturing business; liquidity and the ability of the Company to raise additional financing to continue as a going concern; the Company's ability to meet the demand for flower in Minnesota; risk of failure in the lawsuit with Verano and the cost of that litigation; our ability to dispose of our assets held for sale at an acceptable price or at all; and risk factors set out in the Company's Form 10-K for the year ended December 31, 2023, which will be available later today on EDGAR with the U.S. Securities and Exchange Commission and filed with the Canadian securities regulators and available under the Company's profile on SEDAR at www.sedar.com .
The statements in this press release are made as of the date of this release. Except as required by law, we undertake no obligation to update any forward-looking statements or forward-looking information to reflect events or circumstances after the date of such statements.
News Provided by GlobeNewswire via QuoteMedia
Investing News Network websites or approved third-party tools use cookies. Please refer to the cookie policy for collected data, privacy and GDPR compliance. By continuing to browse the site, you agree to our use of cookies.